Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
REGULATORY
Keytruda SC Heads to Japan Approval, Ipsen’s Ojemda for Conditional Nod
A key Japanese health ministry panel on August 24 recommended approval of a batch of new medicines and indications including a subcutaneous version of MSD’s PD-1 inhibitor Keytruda (pembrolizumab) and Ipsen’s targeted glioma therapy tovorafenib, known as Ojemda. The Pharmaceutical…
To read the full story
Related Article
- Japan Doles Out Orphan Tags to Givinostat, Apitegromab, and Lots More
September 28, 2026
- Japan Approves Keytruda, Leqembi SC Formulations, Xcopri, and More Drugs
September 17, 2026
- Japan Panel to Weigh Keytruda SC, J&J Psoriasis Pill among 6 NMEs on Aug. 24
August 18, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- J&J Files Tecvayli/Darzquro Combo for MM in Japan
February 12, 2026
- Ohara Files Japan NDA for Jazz’s Diffuse Midline Glioma Drug
February 2, 2026
- Takeda Files ImmunoGen-Paired ADC for Ovarian Cancer in Japan
February 2, 2026
- Japan Panel Green-Lights Pfizer’s Tukysa, Wider Labels for Tezspire, and More Drugs
January 30, 2026
- J&J Files Oral Psoriasis Drug Icotrokinra in Japan
November 10, 2025
- MSD Seeks Capvaxive Use in High-Risk Children in Japan
November 10, 2025
- MSD Files for Keytruda Label Expansion in Ovarian Cancer
October 31, 2025
- AbbVie Files Skyrizi for Pediatric Dosage in Japan
October 30, 2025
- Enhertu Combo Filed for First-Line HER2 Breast Cancer in Japan
October 8, 2025
REGULATORY
- MOF Presses for Full FY2027 Drug Price Revision Without Price Gap Thresholds
November 4, 2026
- Japan Panel to Review Kyowa Kirin’s Libmeldy for Approval on Nov. 9
November 4, 2026
- PMDA Sets Out AI Principles for Regulatory Activities, Stresses Human Oversight
November 4, 2026
- Public-Private Pharma Talks Expand to Domestic R&D, Manufacturing Investment
November 2, 2026
- Japan’s Healthcare Spending Hits Record 48.8 Trillion Yen in FY2024
November 2, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…